In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Rigel’s U.S. patents covering TAVALISSE® (fostamatinib disodium hexahydrate) tablets.
The patent information displayed on this page is believed to be accurate as of the most recent update of the page, but should not be considered exhaustive. In particular, omission of a particular patent from this page is not a representation or admission by Rigel that that patent does not cover TAVALISSE® (fostamatinib disodium hexahydrate) tablets and/or one or more of its components.
U.S. Patent Nos.
7,449,458
7,538,108
7,989,448
8,163,902
8,211,889
8,263,122
8,445,485
8,652,492
8,771,648
8,912,170
8,951,504
9,266,912
9,283,238
RE48,898